PRESS-RELEASE ·Filed Apr 17, 2026
Press release · Earnings
Actionable Insight ▲ Bullish
Monitor next 10-Q for GAAP financials to confirm if revenue growth is translating into margin expansion. Canada's rapid uptake could signal scalable international distribution.
Final — all horizons settled through T+60d ⚠ clustered
IMRN ▲ +29.44% at T+60d
LONG call ✓ call won +29.44% · α vs SPY +23.29% · entry $0.9580 → $1.24
T+1d
0.00%
call 0.00% · α +0.19%
$0.9580
settled 6mo ago
T+5d
-6.68%
call -6.68% · α -7.24%
$0.8940
settled 6mo ago
T+20d
+15.87%
call +15.87% · α +10.50%
$1.11
settled 6mo ago
T+60d
+29.44%
call +29.44% · α +23.29%
$1.24
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Immuron Limited reported unaudited Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by strong growth in Australia and Canada, with U.S. sales flat. Full financial results including EPS were not disclosed.
Key Financial Metrics
Revenue
$1.0M
est $0.00 · +16.0% YoY
Key Facts
- Q3 global sales: AUD$1.5 million (+16% YoY)
- Australia Q3 sales: AUD$0.9 million (+15% YoY)
- Canada Q3 sales: AUD$0.1 million (+82% QoQ, >100% YoY)
- USA Q3 sales: AUD$0.5 million (+1% YoY)
- YTD sales: AUD$5.7 million (+7% YoY)
- No EPS or profitability data disclosed
Financial Impact
Sales growth of 16% YoY to AUD$1.5 million (~$1.02M USD), with Canada showing explosive sequential growth
revenuegeographic_segment_performance
Risk Factors
- Currency risk from AUD/USD exchange rate fluctuations
- Lack of disclosed profitability or EPS data limits fundamental assessment
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276005 |
26 reports for IMRN
100% Hit rate @ T+60 Went positive at some point 3 of 3 best @ T+60▲ +29.44%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9434 (+1.44%) |
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9434 (+1.22%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9434 (+1.22%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9434 (−0.59%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9434 (−3.94%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9434 (−9.29%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9434 (−20.72%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9434 (−20.72%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9434 (−24.83%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9434 (−47.59%) |
Showing 10 of 26
US Market Status
Market Open — Closes in 1h 50m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers